Mochida Pharmaceutical Co., Ltd. (DE:MFY)
FRANKFURT:MFY
MFY Stock Chart & Stats
€17.10
-€0.20(-0.98%)
At close: 4:00 PM EST
€17.10
-€0.20(-0.98%)
Day’s Range― - ―
52-Week Range€16.20 - €21.80
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€650.32M
Enterprise Value€93.93B
Total Cash (Recent Filing)€54.69B
Total Debt (Recent Filing)€830.00M
Price to Earnings (P/E)12.6
Beta0.42
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding36,390,000
10 Day Avg. Volume4
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.13
Revenue Forecast (FY)€597.52M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage and a robust equity ratio give Mochida durable financial flexibility to fund R&D, pursue licensing or selective M&A, and absorb reimbursement or pricing pressure without refinancing risk. This strengthens long-term stability and preserves optionality for strategic moves.
Healthy Gross And Net MarginsConsistently healthy gross and net margins reflect disciplined cost control and pricing power in its specialty therapeutic areas. Margin resilience supports sustained profitability, enables reinvestment into clinical programs and MR-driven promotion, and cushions against modest revenue slowdowns.
Strong Cash Conversion Vs. EarningsA strong free cash flow to net income ratio and recent improvement in operating cash flow show the company can convert earnings into cash. Reliable cash conversion supports ongoing R&D, dividend distribution, and licensing investments, underpinning medium-term financial resilience.
Bears Say
Declining Revenue Growth TrendA multi-year decline in revenue growth, capped by a significant recent drop, signals product lifecycle pressures or loss of market momentum. Persistent top-line weakness constrains internal funding for development, limits scale benefits, and raises questions about sustainable long-term organic growth.
Volatile Free Cash Flow GrowthVolatility in free cash flow growth reduces predictability for capital allocation and strategic planning. Swinging FCF can disrupt steady R&D investment, dividend policy, or balance sheet strengthening, increasing the company's vulnerability to revenue or reimbursement shocks over the medium term.
Concentration In Domestic MarketHeavy reliance on the Japanese prescription market concentrates regulatory, reimbursement, and demographic risks. Limited geographic diversification restricts revenue expansion opportunities and makes long-term growth more sensitive to domestic policy shifts or slower market dynamics versus peers with broader international footprints.
Mochida Pharmaceutical Co., Ltd. News
MFY FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was €16.20 and its highest was €21.80 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is €650.32M.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 40 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Feb 06, 2026. The company reported €0.381 earnings per share for the quarter, beating the consensus estimate of N/A by €0.381.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. does not currently pay dividends.
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of €0.381 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.528%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in DE:MFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---